TAKE ON
WINTER.
1 – 3
SYMBICORT ® reduced asthma exacerbations during winter
vs. pooled maintenance ICS / LABA + SABA( RR 0.56; 95 % CI 0.49 – 0.64; P < 0.001) retrospective analysis in mild-to-moderate asthma * 1
* Data from a retrospective analysis of five double-blind, randomised, parallel-group clinical studies of 6 – 12 months duration( N = 12,507), running across summer and winter periods in the northern and southern hemispheres, investigating the efficacy of Symbicort ® compared with pooled data from three comparator regimens of fixed-dose maintenance treatment( higher maintenance dose ICS, same-dose maintenance ICS / LABA and higher-dose maintenance ICS / LABA each with as-needed SABA). Eligible patients were prescribed GINA Step 2 – 4 treatment before entry into the study, and had one or more asthma exacerbations in the previous year, bronchodilator reversibility and suboptimally controlled asthma during the run-in period. A severe exacerbation was defined as deterioration in asthma resulting in OCS use for ≥3 days and / or hospitalisation / emergency room treatment. The prescription of OCS was according to the clinical judgement of the physician, who was unaware of the patient’ s( double-blind) treatment allocation. Milder exacerbations and those identified in two studies only by a fall in morning peak flow were excluded. 1 Safety: Adverse reactions, which have been associated with budesonide, formoterol and Symbicort ® are as follows: Common: tremor, palpitations, oropharyngeal candidiasis, headache, throat irritations, coughing, hoarseness, pneumonia( in COPD patients); others, see full PI. 2, 3 Please review Product Information for each product for full prescribing details. Precautions: Therapy should not be initiated to treat a severe exacerbation; not for initiation of ICS in patients transferring from oral steroids; impaired adrenal function; infections of the respiratory system; sensitivity to sympathomimetic amines; severe cardiovascular conditions; hypokalaemia; diabetes; impaired renal and hepatic function; pregnancy( category B3); lactation; children < 12 years. 2, 3
PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR WWW. ASTRAZENECA. COM. AU / PI OR BY SCANNING THIS QR CODE.
Symbicort ® Turbuhaler ®( budesonide / formoterol fumarate dihydrate) I Symbicort ® Rapihaler ®( budesonide / formoterol fumarate dihydrate)
Symbicort ® is indicated in adults and adolescents, for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations. 2, 3
PBS Information: Authority Required( STREAMLINED) for Asthma and COPD. Refer to PBS Schedule for full authority benefit information.
SCAN QR CODE to see full
Symbicort ®
Product Information
GINA = Global Initiative for Asthma; ICS = inhaled corticosteroid; LABA = long-acting beta 2 agonists; OCS = oral corticosteroid; RR = rate ratio; SABA = short-acting beta 2 agonists.
References: 1. Reddel HK et al. Eur Respir J. 2011; 38( 3): 584 – 593( including supplementary information). 2. Symbicort ® Turbuhaler ® Approved Product Information. 3. Symbicort ® Rapihaler ® Approved Product Information. Symbicort, ® Turbuhaler ® and Rapihaler ® are registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www. astrazeneca. com. au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via https:// contactazmedical. astrazeneca. com. 2824. AU-22213 _ AD. May 2025.